Iovance Biotherapeutics Competitors and Similar CompaniesClear all
Iovance Biotherapeutics's competitors and similar companies include Achilles Therapeutics, Kyowa Kirin, ARIAD Pharmaceuticals and CytomX Therapeutics.
 Iovance Biotherapeutics Iovance Biotherapeutics (formerly Lion Biotechnologies) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes. |  Achilles Therapeutics Achilles Therapeutics is a developer of immunotherapies intended to offer therapies to treat cancer. |  Kyowa Kirin Kyowa Kirin (formerly Kyowa Hakko Kirin) is a pharmaceutical company focused on the areas of oncology, nephrology, immunology, and the central nervous system. |  ARIAD Pharmaceuticals ARIAD Pharmaceuticals is a global oncology company focused on discovering, developing and commercializing precision therapies for patients with rare cancers. |  CytomX Therapeutics CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on Probody technology platform. | |
Founding Date | Founding Date 2013 | Founding Date 2016 | Founding Date 2008 | Founding Date 1991 | Founding Date 2008 |
Type | Type Public | Type Private | Type Public | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations San Carlos, US HQ New York, US Philadelphia, US Philadelphia, US Tampa, US | Locations London, GB HQ Stevenage, GB | Locations Cambridge, US HQ Boston, US Chicago, US Cincinnati, US Dallas, US Minneapolis, US New York, US see more | Locations South San Francisco, US HQ | |
Employees | Employees 14868% increase | Employees 695% decrease | Employees 5,669 | Employees 1381% increase | Employees 15815% increase |
Valuation ($) | Valuation ($) 3.3 b | Valuation ($) N/A | Valuation ($) 8.8 b | Valuation ($) N/A | Valuation ($) 78 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $263.5m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) ¥496.8b (FY, 2025) | Revenue (est.) $118.8m (FY, 2015) | Revenue (est.) $76.2m (FY, 2025) |
Cost of goods | Cost of goods $173.2m (FY, 2025) | Cost of goods N/A | Cost of goods ¥114.3b (FY, 2025) | Cost of goods $2.1m (FY, 2015) | Cost of goods N/A |
Gross profit | Gross profit $90.3m (FY, 2025) | Gross profit N/A | Gross profit ¥383.4b (FY, 2025) | Gross profit $116.7m (FY, 2015) | Gross profit N/A |
Net income | Net income N/A | Net income ($69.7m) (FY, 2023) | Net income ¥67b (FY, 2025) | Net income ($231.2m) (FY, 2015) | Net income ($17.4m) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised $ 100m | Total funding raised $ 138.1m | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 132.4m |
For sources of this data, please see the company profile
View Company Profiles
Achilles Therapeutics
HQ
London, GB
Employees
69↓ 5% decrease
Achilles Therapeutics is a developer of immunotherapies intended to offer therapies to treat cancer.
View companyKyowa Kirin
HQ
Tokyo, JP
Employees
5,669
Kyowa Kirin (formerly Kyowa Hakko Kirin) is a pharmaceutical company focused on the areas of oncology, nephrology, immunology, and the central nervous system.
View companyARIAD Pharmaceuticals
HQ
Cambridge, US
ARIAD Pharmaceuticals is a global oncology company focused on discovering, developing and commercializing precision therapies for patients with rare cancers.
View companyCytomX Therapeutics
HQ
South San Francisco, US
Employees
158↑ 15% increase
CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on Probody technology platform.
View company